Cargando…

Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease

The antifibrotic therapies nintedanib and pirfenidone were first approved by the United States for the treatment of idiopathic pulmonary fibrosis in 2014. In 2020, nintedanib received U.S. Food and Drug Administration (FDA) approval for the treatment of all progressive fibrosing interstitial lung di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilfong, Erin M., Aggarwal, Rohit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Interstitial Lung Disease in Autoimmune Rheumatic Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669869/ https://www.ncbi.nlm.nih.gov/pubmed/34917177 http://dx.doi.org/10.1177/1759720X211060907

Ejemplares similares

The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease
por: Liang, Minrui, et al.
Publicado: (2022)

The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease
por: Boleto, Gonçalo, et al.
Publicado: (2022)

Biomarkers for interstitial lung disease and acute-onset diffuse interstitial lung disease in rheumatoid arthritis
por: Furukawa, Hiroshi, et al.
Publicado: (2021)

Interstitial lung disease pathology in systemic sclerosis
por: Konopka, Kristine E., et al.
Publicado: (2021)

Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders
por: Kuwana, Masataka, et al.
Publicado: (2021)

Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders
por: Panagopoulos, Panagiotis, et al.
Publicado: (2021)

Systemic sclerosis associated interstitial lung disease: a survey of current practices in France
por: Nicolas, Amélie, et al.
Publicado: (2023)

Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all
por: Spierings, J., et al.
Publicado: (2021)

Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review
por: Depascale, Roberto, et al.
Publicado: (2021)

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
por: Wright, William Alexander, et al.
Publicado: (2021)

National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care
por: Salonen, Johanna, et al.
Publicado: (2022)

Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis
por: Aoshima, Yoichiro, et al.
Publicado: (2021)

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
por: Saketkoo, Lesley Ann, et al.
Publicado: (2014)

Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin
por: Arai, Toru, et al.
Publicado: (2021)

CD4+T cells in ageing-associated interstitial lung abnormalities show evidence of pro-inflammatory phenotypic and functional profile
por: Machahua, Carlos, et al.
Publicado: (2021)

Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services
por: Barratt, Shaney L, et al.
Publicado: (2021)

Analytic Morphomics in Myositis-Related Interstitial Lung Disease
por: O’Mahony, Alexander T., et al.
Publicado: (2023)

Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)
por: Wild, Jim M, et al.
Publicado: (2021)

Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3p
por: Guiot, Julien, et al.
Publicado: (2020)

Diagnoses and treatments for participants with interstitial lung abnormalities detected in the Yorkshire Lung Screening Trial
por: Upperton, Sara, et al.
Publicado: (2023)

Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial
por: Arai, Toru, et al.
Publicado: (2020)

Feasibility of cardiopulmonary exercise testing in interstitial lung disease: the PETFIB study
por: Tomlinson, Owen, et al.
Publicado: (2021)

Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry
por: Tsubouchi, Kazuya, et al.
Publicado: (2023)

Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases
por: Salonen, Johanna, et al.
Publicado: (2020)

Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians
por: Althobiani, Malik, et al.
Publicado: (2021)

Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review
por: Shah Gupta, Rikisha, et al.
Publicado: (2023)

Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study
por: Troy, Lauren K, et al.
Publicado: (2019)

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
por: Corte, Tamera J, et al.
Publicado: (2021)

Predictors of postoperative acute exacerbation of interstitial lung disease: a case–control study
por: Hosoki, Keisuke, et al.
Publicado: (2020)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference
por: Sinha, Aish, et al.
Publicado: (2019)

Patient perspectives on home-spirometry in interstitial lung disease: a qualitative co-designed study
por: Mandizha, Jessica, et al.
Publicado: (2023)

Defining the pathway to timely diagnosis and treatment of interstitial lung disease: a US Delphi survey
por: Case, Amy Hajari, et al.
Publicado: (2023)

Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses
por: Fields, Aislin, et al.
Publicado: (2023)

Central lung gene expression associates with myofibroblast features in idiopathic pulmonary fibrosis
por: Huang, Yong, et al.
Publicado: (2023)

Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis
por: Nayebirad, Sepehr, et al.
Publicado: (2023)

Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy
por: Sgalla, Giacomo, et al.
Publicado: (2015)

In vivo polarisation sensitive optical coherence tomography for fibrosis assessment in interstitial lung disease: a prospective, exploratory, observational study
por: Vaselli, Margherita, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2d41l1vjsd3mcfffmrbtki8hv6